COMMISSION IMPLEMENTING DECISION

of 21.3.2018


(Text with EEA relevance)

(ONLY THE FRENCH TEXT IS AUTHENTIC)
COMMISSION IMPLEMENTING DECISION

of 21.3.2018


(Text with EEA relevance)

(ONLY THE FRENCH TEXT IS AUTHENTIC)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency 1, and in particular Article 10(2) thereof,

Having regard to the application submitted by GlaxoSmithKline Biologicals S.A., on 23 December 2016, under Article 4(1) of Regulation (EC) No 726/2004,

Having regard to the opinion of the European Medicines Agency, formulated on 25 January 2018 by the Committee for Medicinal Products for Human Use,

Whereas:


(2) It is therefore appropriate to authorise its placing on the market.

(3) The Committee for Medicinal Products for Human Use considered that "Varicella Zoster Virus glycoprotein E antigen" is a new active substance.

(4) The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on Medicinal Products for Human Use,

HAS ADOPTED THIS DECISION:

Article 1

The marketing authorisation provided for in Article 3 of Regulation (EC) No 726/2004 is granted for the medicinal product "Shingrix - herpes zoster vaccine (recombinant, adjuvanted)", the characteristics of which are summarised in Annex I to this Decision.

"Shingrix - herpes zoster vaccine (recombinant, adjuvanted)" shall be registered in the Community register of medicinal products under number EU/1/18/1272.

Article 2
The marketing authorisation concerning the medicinal product referred to in Article 1 shall be subject to compliance with the conditions set out in Annex II and, in particular, with those relating to manufacture and importation, control and issue.

Article 3
The labelling and package leaflet concerning the medicinal product referred to in Article 1 shall comply with the conditions set out in Annex III.

Article 4
The period of validity of the authorisation shall be five years from the date of notification of this Decision.

Article 5
This Decision is addressed to GlaxoSmithKline Biologicals S.A., rue de l'Institut 89, 1330 Rixensart, Belgique.
Done at Brussels, 21.3.2018

For the Commission
Xavier PRATS MONNÉ
Director-General